Posted by Michael Wonder on 05 Nov 2025
Advicenne has submitted to US FDA the registration application for Sibnayal in dRTA treatment
4 November 2025 - Advicenne announces the submission of the registration application for Sibnayal (fixed-dose combination of potassium citrate and potassium bicarbonate) for the treatment of distal renal tubular acidosis to the US FDA.
Sibnayal has been designated orphan drug in distal renal tubular acidosis in the USA.
